Listed

Corcept Therapeutics Inc

CORTNasdaqCIK 1088856HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$256.1mRevenue, Q2 FY2026, three months to 2026-06-30$256.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 29, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$256.1mRevenue, Q2 FY2026, three months to 2026-06-30$256.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure+31.7% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin16.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $41.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Revenue: $256.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure+2.4 pts on a year earlier
  • Net margin16.8%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $43.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Revenue: $256.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure−1.3 pts on a year earlier
  • Diluted EPS$0.36Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure+24.1% on a year earlier
  • Free cash flow$31.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $33.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-29, accession 0001628280-26-050613. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-29, accession 0001628280-26-050613. Derived: 6-month figure less the 3-month figure.Report this figure−29.9% on a year earlier

Last eight quarters

Full statements
Revenue$256.1mOperating margin 16.1%
Diluted EPS$0.36, Q2 FY2026
Free cash flow$31.0m, Q2 FY2026
Corcept Therapeutics Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m183Revenue, Q3 FY2024, three months to 2024-09-30$182.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Report this figure182Revenue, Q4 FY2024, three months to 2024-12-31$181.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Report this figure157Revenue, Q1 FY2025, three months to 2025-03-31$157.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure194Revenue, Q2 FY2025, three months to 2025-06-30$194.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure208Revenue, Q3 FY2025, three months to 2025-09-30$207.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Report this figure202Revenue, Q4 FY2025, three months to 2025-12-31$202.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Report this figure165Revenue, Q1 FY2026, three months to 2026-03-31$164.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure256Revenue, Q2 FY2026, three months to 2026-06-30$256.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%25.5%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $46.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Revenue: $182.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Report this figure13.9%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $25.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Revenue: $181.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Report this figure2.2%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Revenue: $157.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure13.7%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $26.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Revenue: $194.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure4.9%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $10.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Revenue: $207.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Report this figure2.2%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Revenue: $202.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Report this figure(30.1%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$49.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Revenue: $164.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure16.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $41.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Revenue: $256.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure
Net margin%25.9%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $47.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Revenue: $182.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Report this figure16.9%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $30.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Revenue: $181.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Report this figure13.1%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $20.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Revenue: $157.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure18.1%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $35.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Revenue: $194.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure9.5%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $19.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Revenue: $207.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Report this figure12.0%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $24.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Revenue: $202.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Report this figure(19.3%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$31.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Revenue: $164.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure16.8%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $43.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Revenue: $256.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure
Diluted EPS$ per share0.41Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Report this figurenot reported (Diluted EPS not reported)0.17Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure0.29Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure0.16Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001628280-25-048841.Report this figurenot reported (Diluted EPS not reported)(0.30)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure0.36Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-29, accession 0001628280-26-050613.Report this figure
Free cash flow$m71.7Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $73.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001628280-25-048841. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001628280-25-048841. Derived: 9-month figure less the 6-month figure.Report this figure59.9Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $60.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Capital expenditure: $121.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Report this figure4.7Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Capital expenditure: $104.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure44.2Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $44.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-29, accession 0001628280-26-050613. Derived: 6-month figure less the 3-month figure.Capital expenditure: $57.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-29, accession 0001628280-26-050613. Derived: 6-month figure less the 3-month figure.Report this figure54.5Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $54.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001628280-25-048841. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001628280-25-048841. Derived: 9-month figure less the 6-month figure.Report this figure38.4Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $38.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Capital expenditure: $50.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011091. Derived: 12-month figure less the 9-month figure.Report this figure(17.0)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$16.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Capital expenditure: $201.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001628280-26-028902.Report this figure31.0Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $33.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-29, accession 0001628280-26-050613. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-29, accession 0001628280-26-050613. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$761.4mOperating margin 5.9%
Diluted EPS$0.82, FY2025
Free cash flow$141.8m, FY2025
Corcept Therapeutics Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m366Revenue, FY2021, twelve months to 2021-12-31$366.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-15, accession 0001628280-24-005055.Report this figure402Revenue, FY2022, twelve months to 2022-12-31$401.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-26, accession 0001628280-25-008167.Report this figure482Revenue, FY2023, twelve months to 2023-12-31$482.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure675Revenue, FY2024, twelve months to 2024-12-31$675.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure761Revenue, FY2025, twelve months to 2025-12-31$761.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%34.0%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $124.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-15, accession 0001628280-24-005055.Revenue: $366.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-15, accession 0001628280-24-005055.Report this figure28.0%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $112.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-26, accession 0001628280-25-008167.Revenue: $401.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-26, accession 0001628280-25-008167.Report this figure22.2%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $107.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091.Revenue: $482.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure20.3%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $137.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091.Revenue: $675.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure5.9%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $44.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091.Revenue: $761.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure
Net margin%30.7%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $112.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-15, accession 0001628280-24-005055.Revenue: $366.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-15, accession 0001628280-24-005055.Report this figure25.2%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $101.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-26, accession 0001628280-25-008167.Revenue: $401.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-26, accession 0001628280-25-008167.Report this figure22.0%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $106.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091.Revenue: $482.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure20.9%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $141.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091.Revenue: $675.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure13.1%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $99.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011091.Revenue: $761.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure
Diluted EPS$ per share0.89Diluted EPS, FY2021, twelve months to 2021-12-31$0.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-15, accession 0001628280-24-005055.Report this figure0.87Diluted EPS, FY2022, twelve months to 2022-12-31$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-26, accession 0001628280-25-008167.Report this figure0.94Diluted EPS, FY2023, twelve months to 2023-12-31$0.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure1.23Diluted EPS, FY2024, twelve months to 2024-12-31$1.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure0.82Diluted EPS, FY2025, twelve months to 2025-12-31$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure
Free cash flow$m167Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $167.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-15, accession 0001628280-24-005055.Capital expenditure: $469.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-15, accession 0001628280-24-005055.Report this figure120Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $120.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-26, accession 0001628280-25-008167.Capital expenditure: $413.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-26, accession 0001628280-25-008167.Report this figure127Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $126.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011091.Capital expenditure: $139.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure196Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $198.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011091.Capital expenditure: $2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure142Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $142.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011091.Capital expenditure: $211.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011091.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Corcept Therapeutics Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$1.08bn12,432,023Added+280,747
RENAISSANCE TECHNOLOGIES LLC2026-06-30$457.5m5,261,628Reduced−421,155
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$438.6m5,044,638Added+224,070
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$362.8m4,172,482Added+95,286
Parallel Advisors, LLC2026-06-30$344.5m3,962,177Reduced−15,227
FMR LLC2026-06-30$290.2m3,337,618Added+147,426
STATE STREET CORP2026-06-30$285.2m3,279,381Added+78,435
AQR CAPITAL MANAGEMENT LLC2026-06-30$224.6m2,582,561Added+2,176,356
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$220.2m2,532,198Reduced−181,321
FIRST TRUST ADVISORS LP2026-06-30$159.1m1,829,545Reduced−343,831

Recent filings

All 1,543 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Corcept Therapeutics Inc, recent filings
FiledFormWhat it isAccession number
2026-09-2308:15 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-398561
2026-07-2916:09 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-050613
2026-07-2916:07 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-050607
2026-06-1716:36 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-274258
2026-06-0308:00 ET8-K8.01 Other events0001193125-26-254622
2026-05-2816:04 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001628280-26-038793
2026-04-3016:14 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-028902
2026-04-3016:11 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-028892
2026-04-1716:08 ETDEF 14AProxy statementPeriod 2026-04-170001628280-26-025735
2026-03-2513:31 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-123543

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 24, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1088856
Tickers
CORT
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:31 ET. Listed shows no prices and gives no investment advice.